AC Immune (NASDAQ:ACIU) Shares Pass Below Fifty Day Moving Average – What’s Next?

Shares of AC Immune (NASDAQ:ACIU) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.95 and traded as low as $2.72. AC Immune shares last traded at $2.84, with a volume of 251,197 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ACIU. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Monday, May 4th. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $7.00 price target on shares of AC Immune in a research report on Friday, March 13th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.50.

AC Immune Stock Performance

The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The company’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $3.09. The stock has a market capitalization of $289.03 million, a price-to-earnings ratio of -3.46 and a beta of 1.65.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. On average, analysts expect that AC Immune will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. EFG International AG bought a new position in shares of AC Immune during the fourth quarter valued at about $41,000. Private Advisor Group LLC bought a new position in shares of AC Immune during the third quarter valued at about $48,000. Sei Investments Co. bought a new position in shares of AC Immune during the second quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its position in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of AC Immune during the third quarter valued at about $63,000. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.